Want to see SHPH full AI Analyst Report?
SHPH Stock Chart & Stats
$1.02
>-$0.01(-1.02%)
At close: 4:00 PM EST
$1.02
>-$0.01(-1.02%)
Day’s Range― - ―
52-Week Range$2.90 - $55.90
Previous CloseN/A
Volume45.16K
Average Volume (3M)424.69K
Market Cap
$2.28M
Enterprise Value$1.68M
Total Cash (Recent Filing)$1.09M
Total Debt (Recent Filing)$214.01K
Price to Earnings (P/E)―
Beta1.25
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding637,108
10 Day Avg. Volume561,719
30 Day Avg. Volume424,685
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.31
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.82
Enterprise Value/Ebitda-0.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic Management RestructuringThe appointment of a new interim CEO and CSO aims to enhance business focus and capital market engagement, potentially improving strategic execution and financial management.
Successful FundraisingThe successful fundraising provides critical capital to fund Phase II clinical trials and meet Nasdaq’s equity requirements, supporting operational continuity and growth.
Clinical Trial ProgressInvesting in Phase II trials for its lead product candidate indicates progress in product development, which is crucial for future revenue generation and market positioning.
Bears Say
Financial DistressThe lack of revenue and ongoing losses highlight financial instability, posing risks to sustainability and necessitating urgent strategic and operational adjustments.
High Debt LevelsThe high-interest revolving loan adds financial strain, increasing debt burden and interest obligations, which could limit operational flexibility and strategic options.
Negative Cash FlowPersistent negative cash flow reflects unsustainable operations, requiring effective cost management and revenue generation strategies to ensure long-term viability.
Shuttle Pharmaceuticals Holdings, Inc. News
SHPH FAQ
What was Shuttle Pharmaceuticals Holdings, Inc.’s price range in the past 12 months?
Shuttle Pharmaceuticals Holdings, Inc. lowest stock price was $2.90 and its highest was $55.90 in the past 12 months.
What is Shuttle Pharmaceuticals Holdings, Inc.’s market cap?
Shuttle Pharmaceuticals Holdings, Inc.’s market cap is $2.28M.
When is Shuttle Pharmaceuticals Holdings, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Shuttle Pharmaceuticals Holdings, Inc.’s earnings last quarter?
Currently, no data Available
Is Shuttle Pharmaceuticals Holdings, Inc. overvalued?
According to Wall Street analysts Shuttle Pharmaceuticals Holdings, Inc.’s price is currently Overvalued.
Does Shuttle Pharmaceuticals Holdings, Inc. pay dividends?
Shuttle Pharmaceuticals Holdings, Inc. does not currently pay dividends.
What is Shuttle Pharmaceuticals Holdings, Inc.’s EPS estimate?
Shuttle Pharmaceuticals Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shuttle Pharmaceuticals Holdings, Inc. have?
Shuttle Pharmaceuticals Holdings, Inc. has 637,108 shares outstanding.
What happened to Shuttle Pharmaceuticals Holdings, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Shuttle Pharmaceuticals Holdings, Inc.?
Currently, no hedge funds are holding shares in SHPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings, Inc., in conjunction with its subsidiary Shuttle Pharmaceuticals, Inc., is committed to the identification, advancement, and commercialization of pharmaceutical agents crafted to heighten the susceptibility of cancerous cells to radiation therapy. Its current portfolio of clinical-phase treatments features Ropidoxuridine, an orally administered halogenated pyrimidine, which is intended for individuals afflicted with brain tumors and soft tissue sarcomas. Additionally, the company is progressing Doranidazole, an injectable compound designed to make oxygen-deprived tumor cells more responsive to radiation, targeting malignancies of the pancreas, lungs, and liver. This enterprise was established in 2012 and maintains its principal operations in Rockville, Maryland.
Technical Analysis
China Pharma Holdings
―
Sonoma Pharmaceuticals
―
RedHill Biopharma
―
PainReform
―
Universe Pharmaceuticals
―
Ownership Overview
13.23% Insiders
2.99% Mutual Funds
― Other Institutional Investors
83.78% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---